Remove Biosimilars Remove Compounding Remove Drug Development
article thumbnail

AI and automation to drive “substantial progress” in pharmaceutical analytical testing

European Pharmaceutical Review

The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3

article thumbnail

Global cell line development to surge in next decade

European Pharmaceutical Review

million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 Demand for cell lines “in drug development , vaccine production, and therapeutic research is surging”, setting the market up for significant expansion, Ghosh noted. Total cell line product sales are expected to reach $3,124.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

May 2023 Newsletter

Safe Biologics

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

article thumbnail

May 2023 Newsletter

Safe Biologics

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

article thumbnail

New approvals to revolutionise myelofibrosis treatment landscape across 8MM: GlobalData

Express Pharma

GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.

article thumbnail

Biopharmaceuticals contributing to manufacturing outsourcing trend

European Pharmaceutical Review

As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 This is due to these companies looking to meet to the varied needs of pharmaceutical developers, according to the authors. This is contributing to a more streamlined and efficient approach to drug development, according to the report.

article thumbnail

Novartis to make $300m investment in next-generation biotherapeutics

Pharmaceutical Technology

Together, these strategies are anticipated to boost development processes from pre-clinical to first-in-human clinical trials with quicker transition times. In August, the company announced plans to spin off Sandoz, its generics and biosimilars division , to create a new standalone company.